Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Neurology

When Should CIDP, Anti-MAG, or Protein Tests Be Done?

At a Glance

In suspected CIDP, monoclonal protein screening is generally recommended for everyone; anti-MAG and nodal antibody tests are usually considered only when symptoms, nerve studies, or treatment response suggest a related disorder.

In this answer

4 sections

01

1. Monoclonal Protein Testing: The General Screen

02

2. Nodal/Paranodal Antibodies (NF155, CNTN1, CASPR1)

03

3. Anti-MAG Testing: When Sensory Symptoms Dominate

04

Why Your Specific Symptoms (Phenotype) Matter Most

If you are being evaluated for chronic inflammatory demyelinating polyneuropathy (CIDP), your doctor may order specialized tests to look for specific antibodies or abnormal proteins. As a general rule, everyone evaluated for CIDP should be screened for monoclonal proteins [1][2]. However, specialized antibody tests (like nodal/paranodal or anti-MAG) are not routine for everyone; they are ordered when your specific symptoms, nerve conduction tests, or treatment responses suggest you might have a distinct but closely related nerve disorder [3][4].

Safety Note: If you experience rapid worsening of weakness, new trouble breathing or swallowing, or major facial weakness, contact your care team urgently for clinical assessment. Do not wait for a blood test result to seek help.

1. Monoclonal Protein Testing: The General Screen

Every patient being evaluated for suspected CIDP should be screened for monoclonal proteins (also called paraproteins) [1][2]. These are abnormal, identical proteins produced by a clone of immune cells.

Finding a monoclonal protein does not mean you have cancer [5]. Often, it represents a non-cancerous condition called MGUS (monoclonal gammopathy of undetermined significance) [6]. However, identifying it is a crucial step to rule out “lookalike” diseases that mimic CIDP, such as POEMS syndrome, AL amyloidosis, or multiple myeloma [6][7].

The Screening Tests:
Screening usually involves blood and sometimes urine tests. A standard serum protein electrophoresis (SPEP) blood test is not sensitive enough on its own [8]. A complete screen typically includes:

  • Serum immunofixation and quantitative immunoglobulins (blood tests to identify the specific type of protein, like IgM, IgG, or IgA) [1][9].
  • Serum free-light-chain testing (a blood test looking for protein fragments; results must be interpreted carefully, as kidney impairment can also alter this ratio) [6][1].
  • Urine immunofixation, if clinically indicated to look for proteins in the urine [10][11].

If your initial tests are clear but your neuropathy worsens, or if you develop new systemic symptoms, your doctor may repeat the tests, as these proteins can develop later [12][13]. The timing for repeat testing depends on your doctor’s clinical suspicion.

When a Hematology Assessment is Appropriate

If any new or unexplained monoclonal protein is found, your neurologist may refer you to a hematologist (a blood specialist) to characterize it. This is especially true if:

  • An IgM monoclonal protein is found, which can be associated with Waldenström macroglobulinemia or anti-MAG neuropathy [1][14].
  • You have an unexplained abnormal free-light-chain ratio, which may prompt evaluation for AL amyloidosis [15][6].
  • You develop systemic features like unexplained weight loss, heart problems, severe swelling, bone pain, enlarged organs, or skin changes. These clues prompt assessment for systemic diseases [6][7][16].

2. Nodal/Paranodal Antibodies (NF155, CNTN1, CASPR1)

Nerves are wrapped in a protective coating called the myelin sheath. Between the segments of myelin are tiny gaps called the nodes of Ranvier, which help electrical signals jump rapidly down the nerve. Proteins like NF155, CNTN1, and CASPR1 support the specialized junctions (the paranodal axoglial junctions) next to these nodes [3].

Sometimes, antibodies disrupt these junctions. Experts now classify this as an autoimmune nodopathy—a distinct condition that can mimic CIDP clinically but has different underlying biology [3][17].

Clues that may prompt consideration for this testing include:

  • A prominent tremor or severe sensory ataxia (loss of coordination and balance) [17][18].
  • Symptoms that develop rapidly (subacute onset) rather than slowly over many months [17].
  • Cranial nerve involvement, such as facial weakness [18][19].
  • Kidney problems, such as nephrotic-range protein in the urine (proteinuria), which is an uncommon finding sometimes seen with CNTN1 antibodies [18][20].
  • Very high protein levels found in your spinal fluid, though this is also common in ordinary CIDP [19].
  • A poor or fading response to standard Intravenous Immunoglobulin (IVIG) [17][18].
  • Electrodiagnostic (EMG) clues: Nerve conduction tests showing marked distal latency prolongation or patterns that are highly atypical for classic CIDP [21][19].

3. Anti-MAG Testing: When Sensory Symptoms Dominate

Myelin-associated glycoprotein (MAG) is another protein found in the myelin sheath. Antibodies against MAG can be associated with a slowly progressive neuropathy that may be managed differently than classic CIDP [4][22]. Anti-MAG neuropathy is most strongly associated with the presence of an IgM monoclonal protein [4].

Clues that may prompt anti-MAG testing include:

  • A slowly progressive neuropathy primarily affecting sensation (numbness, tingling) rather than muscle strength [4][22].
  • Symptoms starting at the ends of your toes and fingers (distal symptoms) [22].
  • Gait (walking) and balance problems [23].
  • Electrodiagnostic (EMG) clues: A pattern of distal demyelination (nerve signals slowing down most severely at the nerve ends) that requires specialist interpretation [24][25].

Testing is sometimes considered even if a monoclonal protein isn’t initially found, but an isolated, low-level anti-MAG positive result without a compatible phenotype or an IgM monoclonal protein can be nonspecific [26]. A negative initial screen for monoclonal proteins should prompt checking the completeness of testing [13].

Why Your Specific Symptoms (Phenotype) Matter Most

Laboratory tests are powerful, but they must always be interpreted alongside your clinical phenotype—your specific symptoms, disease progression, and nerve conduction results [3][4].

  • Assay Limitations: Antibody assays require highly specific laboratory methods, and false positives can occur [27][28]. A positive result is most reliable when it matches your symptoms, and your doctor may request confirmation testing from a specialized reference laboratory if results are ambiguous [4][29].
  • Anti-MAG Testing Nuances: When using the Bühlmann Titer Unit (BTU) assay, very high levels (e.g., >10,000 BTU) are strongly specific for anti-MAG neuropathy [8]. Lower positive levels (e.g., 1,500 to 7,000 BTU) fall into a “gray zone,” and patients in this range may actually have classic CIDP [8][26]. Cutoffs depend entirely on the specific laboratory and assay used, so always review the lab’s reference range with your doctor.

Important: Do Not Stop Treatment Based on a Blood Test

Never stop or change your IVIG, corticosteroids, or other CIDP treatments solely because of a lab result or a perceived lack of response. These results support clinical decision-making, but any treatment changes should be carefully planned with your treating neurologist [17].

Common questions in this guide

Should everyone being evaluated for CIDP have monoclonal protein testing?
Generally, yes. The evaluation usually includes serum immunofixation, quantitative immunoglobulins, and serum free-light-chain testing, with urine immunofixation when appropriate. A standard SPEP by itself may not detect every clinically important protein.
When might my doctor order nodal or paranodal antibody tests?
These tests are not routine for every person with suspected CIDP. They may be considered when there is a prominent tremor, severe balance or coordination trouble, rapid symptom onset, facial weakness, protein in the urine, unusual nerve-conduction findings, or a poor or fading response to IVIG.
When is anti-MAG testing useful?
Anti-MAG testing is most useful when neuropathy slowly worsens, mainly affects sensation in the toes and fingers, and causes walking or balance problems, especially when an IgM monoclonal protein is present. Nerve-conduction findings showing distal demyelination can also support testing.
Can a positive anti-MAG test confirm that I have anti-MAG neuropathy?
Not by itself. Very high levels in some assays strongly support anti-MAG neuropathy, but lower results may fall into a gray zone and can occur in people with classic CIDP. Doctors interpret the titer using the assay’s reference range, symptoms, nerve studies, and whether an IgM monoclonal protein is present.
Should monoclonal protein testing be repeated if the first results are normal?
It may be appropriate if neuropathy worsens or new systemic symptoms develop, because a monoclonal protein can appear later. The timing and choice of repeat blood or urine tests should be based on your doctor’s clinical assessment.
Does finding a monoclonal protein mean I have cancer?
No. Many monoclonal proteins are related to MGUS, a noncancerous condition, but the finding still needs appropriate evaluation. A neurologist may involve a hematologist, particularly for an IgM protein, an unexplained free-light-chain abnormality, or symptoms such as weight loss, bone pain, swelling, or heart problems.
Should I stop IVIG or corticosteroids if a test is positive?
No; do not stop or change treatment based only on a blood test or perceived lack of response. Antibody and protein results are interpreted with symptoms and nerve studies, and treatment changes should be planned with your treating neurologist.

Related questions

How Long Does It Take to Recover from CIDP Treatment? How Common Is CIDP, and Who Is Most Likely to Get It? Is Nerve Damage From CIDP Permanent or Reversible? Can You Eventually Stop CIDP Treatment and Reach Remission? NF155, CNTN1 & CASPR1: What Do They Mean for Treatment?
Show more
How Does CIDP Differ From Diabetic Neuropathy? Explained What Blood Tests Are Recommended for Suspected CIDP? What Is the IVIG Wear-Off Effect in CIDP Treatment? Why Is a Lumbar Puncture Needed to Help Diagnose CIDP? How Is CIDP Different From ALS, CMT, MMN, and POEMS? Can CIDP Cause One-Sided Symptoms? MADSAM Explained What Is the Difference Between Anti-MAG Neuropathy and CIDP? How CIDP Variants Affect Your Treatment and Prognosis What Causes CIDP, and Can Infections or Vaccines Trigger It? What Should You Do If IVIg or Steroids Fail for CIDP? Autoimmune Nodopathies vs CIDP: What Are the Symptoms? Does CIDP Shorten Life Expectancy? Prognosis Explained Why Is Physical Therapy Important for CIDP Recovery? How Does Efgartigimod (Vyvgart) Work for CIDP Treatment? Is CIDP Hereditary or Contagious? Passing It to Children How Is CIDP Diagnosed and How Long Does Diagnosis Take? Can You Have CIDP With a Borderline or Normal Nerve Study? Can MRI or Ultrasound Diagnose CIDP When Tests Are Unclear? How Do Doctors Distinguish Acute-Onset CIDP From GBS? Do I Need a Nerve Biopsy or Genetic Test for CIDP? Can You Have CIDP Without Muscle Weakness? Explained

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (29)
  1. 1

    Paraproteinemic neuropathies.

    Traub R, Qarni T, Cohen AD, Karam C

    Muscle & nerve 2024; (70(2)):173-179 doi:10.1002/mus.28164.

    PMID: 38816958
  2. 2

    History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Dyck PJB, Tracy JA

    Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.

    PMID: 29866282
  3. 3

    Autoimmune nodopathies: a clinical review.

    Doppler K, Sommer C

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2026; (191()):2112341 doi:10.1016/j.clinph.2026.2112341.

    PMID: 42492459
  4. 4

    Antibody testing in neuropathy associated with anti-Myelin-Associated Glycoprotein antibodies: where we are after 40 years.

    Latov N

    Current opinion in neurology 2021; (34(5)):625-630 doi:10.1097/WCO.0000000000000975.

    PMID: 34267053
  5. 5

    Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

    Chaudhry HM, Mauermann ML, Rajkumar SV

    Mayo Clinic proceedings 2017; (92(5)):838-850 doi:10.1016/j.mayocp.2017.02.003.

    PMID: 28473042
  6. 6

    Top 10 Clinical Pearls in Paraproteinemic Neuropathies.

    Becker B, Stino A

    Seminars in neurology 2025; (45(1)):99-111 doi:10.1055/s-0044-1791769.

    PMID: 39419069
  7. 7

    POEMS Syndrome: Diagnosis and Investigative Work-up.

    Dispenzieri A, Kourelis T, Buadi F

    Hematology/oncology clinics of North America 2018; (32(1)):119-139 doi:10.1016/j.hoc.2017.09.010.

    PMID: 29157614
  8. 8

    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.

    Klein CJ, Triplett JD, Murray DL, et al.

    Neurology 2024; (103(11)):e210000 doi:10.1212/WNL.0000000000210000.

    PMID: 39499873
  9. 9

    Uncommon Presentation of IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Anti-Myelin-Associated Glycoprotein (MAG)-Associated Demyelinating Peripheral Neuropathy as Respiratory Failure: A Case Report.

    Tanariyakul M, Takaoka K, Takahashi T, et al.

    Cureus 2024; (16(6)):e62865 doi:10.7759/cureus.62865.

    PMID: 38912071
  10. 10

    Fibrillary glomerulonephritis combined with chronic inflammatory demyelinating polyneuropathy.

    Sung WK, Jeong JU, Bang KT, et al.

    Kidney research and clinical practice 2015; (34(2)):117-9 doi:10.1016/j.krcp.2014.10.008.

    PMID: 26484033
  11. 11

    [Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]

    Schieferdecker A, Binder M, Weisel K, Bokemeyer C

    Deutsche medizinische Wochenschrift (1946) 2019; (144(14)):982-989 doi:10.1055/a-0832-3393.

    PMID: 31311049
  12. 12

    Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance.

    Fasanya AA, Loncharich MF, Gandhi V, et al.

    Cureus 2016; (8(11)):e899 doi:10.7759/cureus.899.

    PMID: 28070468
  13. 13

    Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.

    Pascual-Goñi E, Martín-Aguilar L, Lleixà C, et al.

    Scientific reports 2019; (9(1)):6155 doi:10.1038/s41598-019-42545-8.

    PMID: 30992531
  14. 14

    Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia.

    Dogliotti I, Jiménez C, Varettoni M, et al.

    Leukemia 2023; (37(2)):388-395 doi:10.1038/s41375-022-01762-3.

    PMID: 36435884
  15. 15

    Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis.

    Chompoopong P, Almarwani B, Katirji B

    Journal of the neurological sciences 2021; (422()):117336 doi:10.1016/j.jns.2021.117336.

    PMID: 33578240
  16. 16

    Clinical Utility of Routine Monoclonal Gammopathy Testing in the Evaluation of Peripheral Neuropathy.

    Maberry MD, Smith CJ, Go RS

    Journal of general internal medicine 2026; (41(3)):753-758 doi:10.1007/s11606-025-09528-0.

    PMID: 40379937
  17. 17

    Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort.

    Broers MC, Wieske L, Erdag E, et al.

    Journal of neurology, neurosurgery, and psychiatry 2023; (95(1)):52-60 doi:10.1136/jnnp-2023-331378.

    PMID: 37879898
  18. 18

    Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

    Delmont E, Brodovitch A, Kouton L, et al.

    Journal of neurology 2020; (267(12)):3664-3672 doi:10.1007/s00415-020-10041-z.

    PMID: 32676765
  19. 19

    Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.

    Tashiro T, Ogata H, Fukami Y, et al.

    Neurology 2025; (105(9)):e214143 doi:10.1212/WNL.0000000000214143.

    PMID: 41052376
  20. 20

    Proteinuria is a key to suspect autoimmune nodopathies.

    Funakoshi K, Kokubun N, Suzuki K, Yuki N

    European journal of neurology 2024; (31(10)):e16406 doi:10.1111/ene.16406.

    PMID: 38980226
  21. 21

    Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins.

    Kouton L, Boucraut J, Devaux J, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2020; (131(4)):921-927 doi:10.1016/j.clinph.2020.01.013.

    PMID: 32078921
  22. 22

    Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management.

    Min YG, Visentin A, Briani C, Rajabally YA

    Journal of neurology, neurosurgery, and psychiatry 2025; (96(4)):340-349 doi:10.1136/jnnp-2024-334678.

    PMID: 39658134
  23. 23

    Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials.

    Latov N, Brannagan TH, Sander HW, Gondim FAA

    Arquivos de neuro-psiquiatria 2024; (82(6)):1-7 doi:10.1055/s-0043-1777728.

    PMID: 38325389
  24. 24

    IgM Flare in Anti-MAG Neuropathy Post Rituximab Treatment: A Clinical Case and a Systematic Review of the Literature.

    Siconolfi G, Vitali F, Sciarrone MA, et al.

    Brain sciences 2024; (14(12)) doi:10.3390/brainsci14121294.

    PMID: 39766493
  25. 25

    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?

    Lozeron P, Ribrag V, Adams D, et al.

    Journal of neurology 2016; (263(9)):1761-70 doi:10.1007/s00415-016-8187-z.

    PMID: 27314957
  26. 26

    A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody.

    Doneddu PE, Ruiz M, Bianchi E, et al.

    European journal of neurology 2023; (30(2)):501-510 doi:10.1111/ene.15296.

    PMID: 35191144
  27. 27

    A Systematic Review and Meta-Analysis of Autoantibodies for Diagnosis and Prognosis in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Guo X, Tang L, Huang Q, Tang X

    Frontiers in neuroscience 2021; (15()):637336 doi:10.3389/fnins.2021.637336.

    PMID: 34108854
  28. 28

    Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies.

    Leto J, Spies J, Tran L, et al.

    Pathology 2025; doi:10.1016/j.pathol.2025.06.009.

    PMID: 41015758
  29. 29

    IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay.

    Kadoya M, Kaida K, Koike H, et al.

    Journal of neuroimmunology 2016; (301()):16-22 doi:10.1016/j.jneuroim.2016.10.013.

    PMID: 27852440

This page is for informational purposes only and does not constitute medical advice. Your neurologist should interpret CIDP-related test results and guide any repeat testing or treatment changes.